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phe discovery of lipoprotein(a) (Lp[a]) traces back to the
960s, with fundamental insights into particle structure and
eritability gained in the 1970s (1,2). Lipoprotein(a) is
omposed of a low-density lipoprotein (LDL) moiety and
he covalently linked carbohydrate-rich apolipoprotein(a)
apo[a]), which is responsible for the unique properties of
he particle. Lipoprotein(a) is a recent evolutionary arrival
pecific to humans and nonhuman primates, with the apo(a)
omponent having originated from a duplication of the
lasminogen gene. Like plasminogen, apo(a) is character-
zed by loop structures called kringles. It contains an inactive
rotease domain, 1 kringle V and 10 different types of
ringle IV motifs, with the kringle IV type 2 (KIV2)
ccurring in multiple copies (3 to 50) regulated by a
opy-number variation in the apo(a) gene. The heterogene-
ty in the number of KIV2 copies accounts for approximately
ne-half of the substantial (up to 1,000-fold) interindividual
ariability of Lp(a) plasma levels. Recent large-scale surveys
nraveled a complex genetic architecture of Lp(a) beyond
he classic copy-number variation (3,4). Multiple (low-
revalence) single-nucleotide polymorphisms in the Lp(a)
ocus on chromosome 6q were reported to partly explain the
ide range of Lp(a) levels in carriers of the same apo(a)
soform and discrepancy in Lp(a) levels between people of
frican descent and whites.
See page 2160
Lipoprotein(a) does not bind to the LDL receptor, and
ccordingly, Lp(a) levels in circulation are not determined
y the efficacy of particle clearance but primarily by its
ynthesis. The well-founded inverse relationship between
p(a) concentration and apo(a) size arises from the lower
ecretion rates in hepatocytes of large apo(a) isoforms. As a
onsequence, the smaller apo(a) phenotype usually domi-
ates in individuals with 2 distinct apo(a) alleles.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
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ustria.Since its discovery, Lp(a) has been recognized to predict
he progression of atherosclerosis and manifestation of its
ain clinical sequelae, myocardial infarction (5,6). A true
isk factor status is strongly corroborated by the: 1) patho-
istologic observation that Lp(a) particles accumulate in
uman atherosclerotic lesions, especially culprit plaques
rone to rupture, but not in normal vasculature; 2) emer-
ence of highly significant associations between genetically
levated levels of Lp(a) and cardiovascular disease, found by
mploying Mendelian randomization approaches (3); and
) amplification of plaque area in atherosclerosis-susceptible
ransgenic mouse and rabbit models expressing apo(a) (6,7).
ipoprotein(a) has been invoked to exert both proathero-
enic and prothrombotic effects in multiple stages of the
therosclerosis process, some of which are apo(a)-dependent
nd others primarily related to the LDL component. In
rief, Lp(a) was shown to promote smooth muscle cell
igration and proliferation by interference with transform-
ng growth factor- activation, induce monocyte chemotac-
ic activity, stimulate endothelial adhesion molecule expres-
ion, and give rise to foam cell formation and lipid-induced
therogenesis analogous to genuine LDL particles but
robably more potent owing to a prolonged residence time
n the vessel wall afforded by its affinity to arterial proteo-
lycans and interaction with fibrin (Fig. 1A). Two injurious
apacities deserve privileged attention. First, an intriguing
eature of apo(a) is the approximately 80% structure homol-
gy with plasminogen, a key component of the endogenous
brinolytic system. Because the protease domain of apo(a)
acks catalytic function, Lp(a) acts as a competitive inhibitor
or plasminogen activation (Fig. 1B), with this capacity
eing more pronounced for low-molecular-weight (LMW)
po(a) isoforms (8). Beyond impairment of clot lysis, Lp(a)
as reported to promote thrombus formation by potentiat-
ng platelet aggregation and stimulating plasminogen acti-
ator inhibitor expression in and release from endothelial
ells and monocytes (Fig. 1B). Epidemiologic evidence for a
rothrombotic action of Lp(a) in vivo is sparse. Analyses in
he Bruneck cohort revealed a highly significant association
etween LMW, but not high-molecular-weight, apo(a)
henotypes and advanced atherogenesis primarily featured
y plaque thrombosis (9). In a recent study (10), LMW
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therothrombotic origin, but not to other stroke subtypes.
Figure 1 Lipoprotein(a)’s Putative Proatherogenic and Prothrom
(A) Proatherogenic and (B) prothrombotic properties in human vasculature (yellow arrecond, Lp(a) was proposed to act as the main scavenger for pxidized phospholipids (OxPLs) in human circulation and
o mediate clearance of these proinflammatory and
c Properties
Most effects are at least in part dependent on apolipoprotein(a) isoform size.boti
ows).roatherogenic adducts via cleavage through lipoprotein-
a
b
h
v
h
t
a
t
i
s
L
o
i
g
b
O
e
a
t
t
t
o
c
f
i
s
w
p
a
t
a
s
d
u
c
a
w
o
t
o
a
p
e
p
e
O
w
a
b
f
r
r
c
p
L
a
u
L
l
p
L
a
c
c
s
a
s
R
p
3
m
R
1
1
1
1
1
K
2170 Kiechl and Willeit JACC Vol. 55, No. 19, 2010
The Mysteries of Lp(a) May 11, 2010:2168–70ssociated phospholipase A2 (Lp-PLA2) (7). The potential
enefit of OxPL binding, however, may turn into harm if
igh levels of Lp(a) with its OxPL load recirculate into the
asculature. Both in vitro experiments and in vivo studies in
umans and transgenic mice expressing Lp(a) demonstrated
hat the vast majority of OxPLs detected by the monoclonal
ntibody E06 travels on Lp(a) (7,11). Of note, the correla-
ion between OxPL and Lp(a) levels is very strong in
ndividuals with small apo(a) isoforms (r  0.95), but less
o in individuals with larger isoforms (r  0.5 to 0.7).
ikewise, Lp-PLA2 activity is several-fold higher on Lp(a)
f individuals with elevated Lp(a) levels and LMW apo(a)
soforms than in equimolar amounts of LDL (7). Trans-
enic mice with mutant apo(a) unable to bind OxPLs have
een developed and will clarify the exact contribution of
xPLs to the atherogenicity of Lp(a). Overall, compelling
vidence from atherosclerosis research suggests that Lp(a) is
potent vascular risk factor and that both Lp(a) concentra-
ion and apo(a) phenotype do matter in this scenario.
In this issue of the Journal, a stimulating meta-analysis by
he team of John Danesh and Santica Marcovina (12) adds
he first large-scale epidemiologic support to a specific role
f apo(a) in cardiovascular disease. That team completed a
hallenging and skillful job in combining aggregated data
rom 40 individual studies with considerable heterogeneity
n laboratory methods and analytic approaches and demon-
trated that subjects with LMW and high-molecular-
eight apo(a) phenotypes—separated by a cut-off of ap-
roximately 22 KIV2 repeats and encompassing about 40%
nd 60%, respectively, of the white population—differ in
heir risk for myocardial infarction and stroke by a factor of
pproximately 2. The strength of association apparently
urpassed that obtained for Lp(a) concentration and vascular
isease in a recent meta-analysis including 126,634 individ-
als (13). Major novelties of the current study are its
onsiderable size, its focus on both myocardial infarction
nd stroke, documentation of consistent associations for a
ide range of circumstances, and various analytic methods
f apo(a) phenotype and genotype assessment (12). Impor-
ant issues that remain to be addressed are the identification
f precise scales of association and actual cut-off values (if
ny), determination of the extent of independency of apo(a)
henotype findings from Lp(a) level, and assessment of
ffect modification by other novel biomarkers. There is
reliminary evidence that Lp(a) affects cardiovascular dis-
ase risk, conditional on the level of (small-dense) LDL,
xPL concentrations, and Lp-PLA2 activity (5–7,14).
Several studies in the general community and in patients
ith advanced kidney disease alike have suggested that
ssessing apo(a) isoforms is of predictive utility above and
eyond the information provided by Lp(a) levels. However,
ormal proof that apo(a) assessment allows for a relevant
eclassification of individual subjects between cardiovascular
isk strata and a significant gain in model discrimination and
alibration remains to be furnished. aIs it time to transfer all of these advances into clinical
ractice? Not yet, but after almost 4 decades of uncertainties in
p(a) research, the puzzling pieces of knowledge are being
ssembled to a promising whole. We are on the verge of
nderstanding the physiologic role and pathologic properties of
p(a) particles and await the development of specific Lp(a)-
owering therapies. Urgent steps to take are to: 1) characterize
otential joint effects of Lp(a)/apo(a), OxPL, (small-dense)
DL, and Lp-PLA2 on atherosclerosis; 2) clarify which
nalytic approach of apo(a) assessment (6,12) best fits the
linical demands; and 3) rigorously test extended risk scores
onsidering Lp(a) level, apo(a) isoforms, or both, on top of
tandard risk factors in various ethnic groups. Concerted efforts
re required to bring more than 40 years of mysteries and
urprises in Lp(a) research to a successful end.
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